Therapeutic Advances in Ophthalmology最新文献

{"title":"Women in vision networks: narrowing the global gender gap in academia.","authors":"Louise Terry, Bethany E Higgins, Dillys A D Amega, Enyam K A Morny, Lindsay Rountree","doi":"10.1177/25158414261451672","DOIUrl":"10.1177/25158414261451672","url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261451672"},"PeriodicalIF":2.0,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anterior segment optical coherence tomography: a tool for infectious keratitis.","authors":"Jaron Sanchez, Mehrnaz Atighehchian, Zahra Bibak-Bejandi, Arash Mirzaei, Kasra Cheraqpour, Mariah Diaz, Emine Esra Karaca, Sarah Miller, Kareena Chawla, Mohammad Soleimani","doi":"10.1177/25158414261449336","DOIUrl":"10.1177/25158414261449336","url":null,"abstract":"<p><p>Infectious keratitis (IK) is a serious vision-threatening ophthalmologic emergency that can lead to irreversible complications such as blindness or corneal scarring. IK can be caused by various types of microorganisms, including bacteria, fungi, protozoa, and viruses, which can cause an inflammatory response and penetrate deep into the cornea, leading to perforation in addition to scarring and ulceration. Given the need for thorough and rapid evaluation of patients with IK, effective ophthalmic imaging techniques that provide both quantitative and qualitative information are essential clinician tools. In this narrative review, we outline the benefits of anterior segment optical coherence tomography as a noninvasive, quantitative and qualitative modality for the supportive assessment of IK and for the longitudinal monitoring of corneal abnormalities that may result from infection.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261449336"},"PeriodicalIF":2.0,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of treatment gap on visual acuity in patients with submacular hemorrhage secondary to neovascular age-related macular degeneration treated with quadruple intervention strategy.","authors":"Agnieszka Joanna Nowosielska, Grzegorz Rotuski","doi":"10.1177/25158414261447184","DOIUrl":"10.1177/25158414261447184","url":null,"abstract":"<p><strong>Background: </strong>Submacular hemorrhage (SMH) is an uncommon complication of neovascular age-related macular degeneration (AMD).</p><p><strong>Objectives: </strong>The study aim was to evaluate the efficacy of combination therapy vitrectomy with subretinal recombinant tissue plasminogen activator (rtPA) given under the retina and anti-VEGF given into the vitreous cavity in patients with SMH based on duration of symptoms and to identify biomarkers to help predict potential visual acuity gain after the procedure.</p><p><strong>Design: </strong>Retrospective case series.</p><p><strong>Methods: </strong>Patients with SMH secondary to AMD were treated with quadruple therapy: (1) vitrectomy; (2) rtPA administration; (3) bevacizumab injection into the vitreous cavity; followed by (4) monthly intravitreal double-dose bevacizumab 2.5 mg.</p><p><strong>Results: </strong>Forty-eight patients were treated (68.8% women; mean age, 80 years). A median of 14 days elapsed between SMH onset and surgical intervention (range, 2-120 days), with vitrectomy performed after ⩾30 days in 39.6% of patients. A significant improvement from baseline in mean best-corrected visual acuity (BCVA) was observed 6 months after SMH treatment (1.6 (baseline) vs 0.9 (Month 6) logMAR; <i>p</i> < 0.001). Overall, 46 (95.8%) patients had improved BCVA and two (4.2%) had stable (unchanged) BCVA in the treated eye. Improvement in BCVA at Month 6 was similar between the cohort with only SMH and patients with coexisting subretinal pigment epithelium hemorrhage (<i>p</i> = 0.11). The main biomarkers predicting surgical outcome were the state of the retina in the foveal center point and hemorrhage thickness. Treatment ⩾30 days after SMH onset resulted in poorer BCVA at Month 6 compared with treatment occurring <30 days after onset (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>A combination of vitrectomy, subretinal rtPA, and bevacizumab, performed in patients with submacular hemorrhage due to neovascular AMD, followed by monthly intravitreal double-dose bevacizumab for SMH, was an effective intervention to achieve visual acuity improvement.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261447184"},"PeriodicalIF":2.0,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative low-level light therapy for ocular surface protection in patients undergoing Femto-LASIK: a prospective double-masked, randomized controlled study.","authors":"Sergio Manuel Solarino, Claudia Cannas, Valerio Calabresi, Filippo Lixi, Mario Troisi, Giorgia Deiana, Roberta Schirru, Assem Namazbayeva, Giulia Coco, Mihaela-Madalina Timofte-Zorila, Daniel Constantin Branisteanu, Giuseppe Giannaccare","doi":"10.1177/25158414261442254","DOIUrl":"10.1177/25158414261442254","url":null,"abstract":"<p><strong>Background: </strong>Dry eye disease (DED) is among the most common complications experienced after femtosecond laser-assisted in situ keratomileusis (Femto-LASIK), often affecting visual recovery, as well as patient satisfaction. Low-level light therapy (LLLT) has shown benefits in various ocular surface diseases, but its role in refractive surgery remains underexplored. This study aimed at evaluating the efficacy of perioperative LLLT in preserving tear film parameters and reducing ocular discomfort symptoms after Femto-LASIK.</p><p><strong>Methods: </strong>In this prospective multicentric, randomized, double-masked, sham-controlled clinical study, adult patients undergoing Femto-LASIK were randomized (1:1) to receive periocular LLLT (633 ± 10 nm, 15 min/session) or sham treatment 7 ± 2 days before and after surgery. Ocular surface evaluation was performed at baseline (T0), and 1 week (T1), 1 month (T2), and 3 months (T3) postoperatively. Outcomes were tear meniscus height (TMH), Schirmer test values, and Dry Eye Questionnaire-5 (DEQ-5) scores, noninvasive tear break-up time (NIBUT), and interferometry.</p><p><strong>Results: </strong>Forty eyes of 40 patients (mean age: 34.58 ± 5.67 years) were analyzed. In the LLLT group, tear film parameters and subjective symptoms remained stable throughout follow-up, with no statistically significant changes over time. Conversely, the control group showed a significant decline in TMH (0.27 ± 0.05 mm to 0.20 ± 0.05 mm; <i>p</i> < 0.001), Schirmer test (20.39 ± 10.84 mm/5' to 15.65 ± 9.02 mm/5'; <i>p</i> = 0.022), and a significant worsening in DEQ-5 scores (3.53 ± 4.10 to 5.94 ± 2.79; <i>p</i> = 0.005). Between-group comparisons demonstrated in the LLLT group significantly higher TMH at T2 (<i>p</i> = 0.034) and T3 (<i>p</i> = 0.016), higher Schirmer values at T2 (<i>p</i> = 0.048) and T3 (<i>p</i> = 0.018), and lower DEQ-5 scores at T1 (<i>p</i> = 0.041), T2 (<i>p</i> = 0.029), and T3 (<i>p</i> = 0.018). NIBUT and interferometry showed no significant between-group differences at any time point. No treatment-related adverse events were observed.</p><p><strong>Conclusion: </strong>Perioperative LLLT appears to be a safe and well-tolerated adjunctive treatment that may help preserve tear volume and support postoperative comfort after Femto-LASIK. These findings suggest a potential role for LLLT in perioperative refractive surgery care, although further studies are warranted to confirm its clinical benefit.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261442254"},"PeriodicalIF":2.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147933757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sectoral excisional goniotomy with Kahook Dual Blade: nasal versus inferior angle treatment.","authors":"Iden Amiri, Obi Wogu, David Fleischman, Rodolfo Bonatti, Meredith R Klifto","doi":"10.1177/25158414261437987","DOIUrl":"10.1177/25158414261437987","url":null,"abstract":"<p><strong>Background: </strong>The Kahook Dual Blade (KDB) is a minimally invasive glaucoma surgery (MIGS) device designed to excise a strip of trabecular meshwork, enhancing aqueous outflow via Schlemm's canal. While its efficacy is well-documented, there is limited evidence comparing outcomes between anatomical quadrants treated.</p><p><strong>Objectives: </strong>To compare intraocular pressure (IOP) reduction, medication burden, visual acuity improvement, and complication rates between nasal and inferior quadrant sectoral excisional goniotomy with KDB combined with cataract surgery.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Medical records of patients with primary open-angle glaucoma who underwent combined phacoemulsification and KDB goniotomy between January 2020 and June 2025 at a single tertiary academic center were reviewed. Patients were grouped by treatment location (nasal vs inferior). Primary outcomes were IOP and the number of glaucoma medications; secondary outcomes included best-corrected visual acuity (BCVA) and adverse events. Multivariate linear regression was used to adjust for baseline differences between groups.</p><p><strong>Results: </strong>Sixty-four eyes (nasal: 50; inferior: 14) met the inclusion criteria. Baseline IOP and BCVA were similar between groups, though the inferior group had fewer medications (1.93 vs 2.68; <i>p</i> = 0.045) and milder visual field loss (MD -8.39 vs -15.18; <i>p</i> = 0.04). Mean treatment extent was approximately 90° in both groups. Both groups achieved significant IOP reduction at all follow-up points, with no long-term differences. At postoperative week 1, the inferior group had higher IOP (18.50 vs 13.99 mmHg; <i>p</i> = 0.0433), potentially due to gravity-dependent hyphema. Medication burden decreased in both groups, with a non-significant trend toward fewer drops in the inferior group. BCVA improved similarly, and complication rates were low and comparable, with no serious adverse events.</p><p><strong>Conclusion: </strong>Nasal and inferior quadrant KDB goniotomy combined with cataract surgery yields comparable long-term outcomes in IOP, medication burden, visual acuity, and safety. Quadrant selection may be guided by intraoperative visualization and patient-specific anatomy without compromising efficacy.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261437987"},"PeriodicalIF":2.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamins and retinitis pigmentosa: a single-center survey from an Italian cohort.","authors":"Maria Ludovica Ruggeri, Alberto Quarta, Carolina Lorenzi, Corina Valentina de Santis Ciacci, Michela Calandra, Roberta Giansante, Lisa Toto, Liborio Stuppia, Rodolfo Mastropasqua","doi":"10.1177/25158414261420920","DOIUrl":"10.1177/25158414261420920","url":null,"abstract":"<p><strong>Background: </strong>Recent evidence has demonstrated the absence of a robust effect of vitamin A on retinitis pigmentosa (RP) patients; however, the actual patients' knowledge on this topic appears to be limited.</p><p><strong>Objectives: </strong>To survey a cohort of Italian patients with a definite diagnosis of RP about their level of knowledge regarding the latest updates on vitamins in RP.</p><p><strong>Design: </strong>Survey study administered between January and June 2025 among patients followed up in a specialized Inherited Retinal Dystrophies (IRD) center in Chieti, Italy, Europe.</p><p><strong>Methods: </strong>Patients were asked a total of 25 questions regarding their dietary attitude. The questionnaire was manually distributed to patients who could answer individually to the survey. To help with significantly visually impaired patients, all patients were offered to be helped by an assistant for reading issues, in accordance with privacy measures.</p><p><strong>Results: </strong>A total of 50 participants were recruited. Of these, 52% of them were taking supplements, 84.6% with vitamin A supplementation, while 7.7% were using multivitamin pills. Participants were surveyed about their knowledge concerning the presence of vitamin A in food, yielding several results: carrots (88%), pumpkin (60%), and kale (60%). Participants referred to exceeding in consuming one of those items in 64% of cases. Specifically, the majority of them overconsumed spinach (62.5%), kale (37.5%), and sweet potatoes (31.3%). While the whole population (100%) was not aware of vitamin impact on certain IRDs, all respondents (100%) manifested their strong interest in gaining knowledge on this topic.</p><p><strong>Conclusion: </strong>Our cohort of Italian patients suffering from syndromic and nonsyndromic RP are not fully aware of the impact of vitamins on their condition, and most of them enrich their diet with nutritional supplements. The implementation of projects aimed at improving knowledge on this topic in the affected population is strongly advised to help with the chronic management of this condition.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261420920"},"PeriodicalIF":2.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13091976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus retinitis in diverse immunocompromised populations: clinical presentation, treatment outcomes, and prognostic factors.","authors":"Seyed Ali Tabatabaei, Arash Mirzaei, Kimia Daneshvar, Ghazal Ghochani, Nader Mohammadi, Mohammadreza Mehrabi Bahar, Zahra Mahdizad, Kosar Esmaeili, Mehdi Aminizade, Morteza Karimi, Pedram Afshar, Amirhossein Valizadeh, Kosar Namakin, Mohamad Sanei, Sarah Miller, Kareena Chawla, Nazanin Ebrahimi Adib, Jaron Sanchez, Mohammad Soleimani","doi":"10.1177/25158414261440308","DOIUrl":"10.1177/25158414261440308","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cytomegalovirus retinitis (CMVR) is a vision-threatening retinal infection that primarily affects severely immunocompromised individuals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;This study aimed to compare the clinical presentations, long-term visual outcomes, and predictors of visual prognosis in CMVR patients across different immunodeficiency subtypes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Retrospective cohort study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study analyzed 117 eyes from 91 patients with CMVR who were treated at a tertiary eye center between 2009 and 2024. Eyes were stratified by the underlying cause of immunosuppression into a human immunodeficiency virus (HIV)-positive group (71 eyes of 58 patients) and an HIV-negative group (46 eyes of 33 patients). The HIV-negative group included patients with hematologic malignancies, drug-induced immunosuppression (e.g., posttransplant or autoimmune therapy), solid organ transplantation, autoimmune disease, congenital immunodeficiency, and poorly controlled diabetes mellitus type 2 (DM2). Patient demographics and comprehensive ophthalmologic examination findings were recorded and compared across these subgroups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study included 91 patients (117 eyes) with a mean age of 40.1 ± 14.7 years; 62.6% were male. Of these, 58 patients (71 eyes) were HIV-positive (mean age 39.7 ± 10.9 years; 65.5% male) and 33 patients (46 eyes) were HIV-negative. Among HIV-negative patients, 19 eyes were in patients with hematologic malignancies (mean age 35.3 ± 21.1 years; 75% male), 20 eyes were in patients with drug-induced immunosuppression (mean age 38.6 ± 17.9 years; 40% male), and the remainder eyes were associated with solid organ transplant, autoimmune disease, congenital immunodeficiency, or poorly controlled DM (7 eyes). Eyes in HIV-negative patients exhibited more severe vitritis than those in HIV-positive patients (34.8% vs 19.7% with vitritis grade +2; &lt;i&gt;p&lt;/i&gt; = 0.009). Conversely, HIV-positive patients presented with worse baseline visual acuity (mean 1.85 ± 1.14 logMAR vs 1.31 ± 1.17 logMAR; &lt;i&gt;p&lt;/i&gt; = 0.045). Comparing the two main HIV-negative subgroups, the drug-induced immunosuppression group showed a significantly higher incidence of retinal vascular sheathing (30% vs 0% of eyes; &lt;i&gt;p&lt;/i&gt; = 0.009), whereas the hematologic malignancy group demonstrated more cotton-wool spots (21.1% vs 0% of eyes; &lt;i&gt;p&lt;/i&gt; = 0.030). Despite these phenotypic differences, long-term visual outcomes were similar across all groups. On multivariable regression, baseline best-corrected visual acuity (BCVA) (β = 0.527, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and retinal detachment (β = 0.254, &lt;i&gt;p&lt;/i&gt; = 0.017) were independent predictors of poorer final visual acuity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;CMV retinitis demonstrates distinct clinical phenotypes in different immunosuppressed populations. HIV-negative patients tend to show more pronounced vitritis and vasculopathic retinal features","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261440308"},"PeriodicalIF":2.0,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13065270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the impact of extraocular disorders and their surgical correction on corneal astigmatism and higher-order aberrations: a comprehensive review.","authors":"Seyed Mohsen Rafizadeh, Hassan Asadigandomani, Omar Nusair, Samin Khannejad, Kimia Vakili, Fatemeh Mahmoudi, Maryam Nassaji, Arash Mirzaei, Mehrdad Mohammadpour, Mohammad Soleimani","doi":"10.1177/25158414261432431","DOIUrl":"10.1177/25158414261432431","url":null,"abstract":"<p><p>Extraocular disorders and their surgical management can significantly influence corneal astigmatism and higher-order aberrations (HOAs). This review aimed to evaluate the relationship between extraocular conditions, their surgical correction, and subsequent changes in corneal astigmatism and HOAs. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, including studies published between 1992 and 2024. Search terms included astigmatism, eyelid surgery, thyroid eye disease (TED), orbital decompression, blepharoplasty, chalazion, dermatochalasis, ptosis, pterygium, scleral buckle, and HOAs. The reviewed literature demonstrates that a wide spectrum of extraocular disorders (such as ptosis, dermatochalasis, TED, chalazion, and pterygium) are associated with clinically significant changes in corneal astigmatism and HOAs. These alterations are affected by factors including lesion size, anatomical location, and the type of surgical intervention. For instance, ptosis surgery may either reduce or induce astigmatism depending on patient age and surgical technique, while chalazion excision and pterygium removal frequently lead to meaningful reductions in astigmatism and HOAs, particularly in cases involving larger lesions. The timing of postoperative evaluation and surgical approach plays a critical role in the magnitude and persistence of these optical changes. Awareness of the impact of extraocular diseases and their surgical treatment on corneal astigmatism and HOAs is essential for accurate interpretation of refractive changes, postoperative follow-up, and optimal patient management.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261432431"},"PeriodicalIF":2.0,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improve harms reporting in trials of microelectronic retinal implants.","authors":"Luke E Hallum, Shaun L Cloherty","doi":"10.1177/25158414261422895","DOIUrl":"10.1177/25158414261422895","url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261422895"},"PeriodicalIF":2.0,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12949783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging drugs for diabetic retinopathy: an overview of therapeutic innovation.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/25158414261422896","DOIUrl":"10.1177/25158414261422896","url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261422896"},"PeriodicalIF":2.3,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12901880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146202804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}